BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Diagnosis
18 results:

  • 1. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
    Staropoli N; Scionti F; Farenza V; Falcone F; Luciano F; Renne M; Di Martino MT; Ciliberto D; Tedesco L; Crispino A; Labanca C; Cucè M; Esposito S; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Arbitrio M
    Biomed Pharmacother; 2024 May; 174():116478. PubMed ID: 38547766
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Contribution of ABCB1 and cyp2d6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.
    Argalácsová S; Slanař O; Vítek P; Tesařová P; Bakhouche H; DraŽďáková M; Bartošová O; Zima T; PertuŽelka L
    Physiol Res; 2015; 64(Suppl 4):S539-47. PubMed ID: 26681084
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. RRM1, TUBB3, TOP2A, CYP19A1, cyp2d6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. cyp2d6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
    Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
    Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.
    Rangel LB; Taraba JL; Frei CR; Smith L; Rodriguez G; Kuhn JG
    Breast Cancer Res Treat; 2014 Dec; 148(3):571-80. PubMed ID: 25395315
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comparative study of polymorphism frequencies of the cyp2d6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
    Alcazar-González GA; Calderón-Garcidueñas AL; Garza-Rodríguez ML; Rubio-Hernández G; Escorza-Treviño S; Olano-Martin E; Cerda-Flores RM; Castruita-Avila AL; González-Guerrero JF; le Brun S; Simon-Buela L; Barrera-Saldaña HA
    Pharmacogenomics; 2013 Oct; 14(13):1583-92. PubMed ID: 24088129
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials.
    Carvalho AF; Hyphantis T; Sales PM; Soeiro-de-Souza MG; Macêdo DS; Cha DS; McIntyre RS; Pavlidis N
    Cancer Treat Rev; 2014 Apr; 40(3):349-55. PubMed ID: 24084477
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Influence of cyp2d6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
    Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
    Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
    Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
    Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Association of polymorphic G1934A variant (allele *4) of cyp2d6 gene with increased risk of breast cancer development in Ukrainian women.
    Levkovich NN; Gorovenko NG; Myasoedov DV
    Exp Oncol; 2011 Sep; 33(3):136-9. PubMed ID: 21956465
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Effect of cyp2d6 polymorphisms on breast cancer recurrence.
    Morrow PK; Serna R; Broglio K; Pusztai L; Nikoloff DM; Hillman GR; Fontecha M; Li R; Michaud L; Hortobagyi G; Gonzalez-Angulo AM
    Cancer; 2012 Mar; 118(5):1221-7. PubMed ID: 21823108
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. cyp2d6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Concurrent use of tamoxifen with cyp2d6 inhibitors and the risk of breast cancer recurrence.
    Azoulay L; Dell'Aniello S; Huiart L; du Fort GG; Suissa S
    Breast Cancer Res Treat; 2011 Apr; 126(3):695-703. PubMed ID: 20848186
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
    Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Association between cyp2d6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
    Onitilo AA; McCarty CA; Wilke RA; Glurich I; Engel JM; Flockhart DA; Nguyen A; Li L; Mi D; Skaar TC; Jin Y
    Breast Cancer Res Treat; 2009 Jun; 115(3):643-50. PubMed ID: 19082882
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Tamoxifen, hot flashes and recurrence in breast cancer.
    Mortimer JE; Flatt SW; Parker BA; Gold EB; Wasserman L; Natarajan L; Pierce JP;
    Breast Cancer Res Treat; 2008 Apr; 108(3):421-6. PubMed ID: 17541741
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.